SSA
CGTX icon

Schonfeld Strategic Advisors’s Cognition Therapeutics CGTX Stock Holding History

Schonfeld Strategic Advisors’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.59K Buy
+10,000
New +$11.6K ﹤0.01% 2106

Other funds holding CGTX

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return

Schonfeld Strategic Advisors's CGTX Position: Q1 2026 in Review

Schonfeld Strategic Advisors opened a new position in Cognition Therapeutics (CGTX) in Q1 2026: 10,000 shares worth $7.59K. The stake represents ﹤0.01% of the portfolio and ranks #2106 among its holdings.

75 funds tracked by Wall St. Rank hold CGTX as of Q1 2026.

  • Schonfeld Strategic Advisors held 10,000 shares of Cognition Therapeutics worth $7.59K as of Q1 2026.
  • Cognition Therapeutics was a new Schonfeld Strategic Advisors position in Q1 2026.
  • Cognition Therapeutics made up ﹤0.01% of Schonfeld Strategic Advisors's portfolio in Q1 2026, its #2106 holding.
  • 75 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.